Implant Sciences to Announce First Quarter FY2016 Financial Results

Company to Report Q1 FY16 Sales Exceed FY15 Total Revenues

05 Nov, 2015, 09:00 ET from Implant Sciences Corporation

WILMINGTON, Mass., Nov. 5, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, will host a webcast and conference call on Thursday, November 12, 2015 at 4:15 p.m. to discuss the financial results for the first quarter of fiscal year 2016.

"We are excited about reporting this quarter's results. Implant Sciences' success, particularly in the European aviation market over the past six months, has led to the best year in the company's history as a manufacturer of explosives trace detection equipment," stated Dr. Bill McGann, CEO of Implant Sciences. "We entered into fiscal 2016 with a backlog of over $40 million based upon our European aviation and TSA orders and I am happy to report that our Q1 sales will exceed our revenues for all of 2015."

"We have built our production capacity to meet our rapid growth and increased demand for our products. We are looking forward to a very strong showing in 2016 and we anticipate continued sales to Europe, the expansion of our sales into the narcotics detection market and delivery of the TSA order," added Robert Liscouski, President of Implant Sciences. "We look forward to sharing the details of our record quarter with our shareholders on the 12th." 

Company Webcast and Conference Call

The Company will host a webcast and conference call on Thursday, November 12, 2015 at 4:15 PM Eastern time to review financial results for the quarter ended September 30, 2015. Following the Company's prepared remarks, there will be a Q&A session. The call can be accessed by dialing: 877-415-3186 within the U.S. or 857-244-7329 outside the U.S. and entering passcode 54186024. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins. A replay of the conference call will be available approximately two hours after the call for one month by dialing: 888-286-8010 within the U.S. or 617-801-6888 outside the U.S. and entering passcode 39267129. The conference call will also be available live over the internet at the "Webcasts" page of the Investor Relations section of Implant Sciences' website at www.implantsciences.com. A replay of the webcast will be available for one month after the call. The company is accepting email questions prior to the call, of which some may be addressed during the question and answer portion of the call. We invite questions to be addressed to ir_imsc@implantsciences.com.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint". All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; the risk that the Company may not be able to meet demand for its products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Implant Sciences Corporation
Roger Deschenes, CFO
(978) 752-1700

SOURCE Implant Sciences Corporation



RELATED LINKS

http://www.implantsciences.com